MARLBOROUGH, Mass. -- Sunovion Pharmaceuticals Inc. (Sunovion) today announced that Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent indicated for the treatment of adult ...

Please provide your email address to receive an email when new articles are posted on . Sunovion recently announced that the FDA approved a supplemental New Drug Application for Latuda for the ...

Sunovion announced positive results from an extension study evaluating the long-term safety, tolerability and efficacy of Latuda (lurasidone HCI) as monotherapy or as an adjunct to lithium or ...

Latuda (lurasidone) is a prescription drug that’s prescribed to treat schizophrenia and bipolar disorder. Latuda comes as a tablet that you take by mouth. Latuda is prescribed to adults, adolescents, ...

Latuda's (lurasidone HCI; Sunovion) expanded indication has been approved for pediatric patients aged 10 to 17 years who have major depressive episodes associated with bipolar I disorder. The Food and ...

As with other drugs, Latuda (lurasidone) can cause side effects, such as restlessness, nausea, and weight gain. If side effects of Latuda become difficult to tolerate, talk with your doctor or ...

Mark Iwicki’s top priority is driving the success of Latuda, an atypical antipsychotic for adults with schizophrenia. “It’s the most important product and business we have for the next couple of years ...

Latuda (lurasidone) is a prescription drug that’s used to treat schizophrenia and depressive episodes related to bipolar I disorder. The drug comes as an oral tablet. It’s usually taken once per day.

Please provide your email address to receive an email when new articles are posted on . Sunovion recently announced positive phase 3 study findings for Latuda for bipolar I disorder depression in ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the U.S. Food and Drug Administration (FDA) has approved LATUDA ® (lurasidone HCl) tablets for the ...

Sunovion Pharmaceuticals turned to artwork for its latest Latuda TV commercial. Paintings inspired by real stories of people with bipolar depression are held by actors who resemble the men and women ...

Sunovion Pharmaceuticals Inc., a Marlborough based drug company now owned by Dainippon Sumitomo Pharma Co. Ltd. of Japan, said that it has received regulatory approval to market its Latuda drug for ...